Ma Y H, Bruin T, Tuzgol S, Wilson B I, Roederer G, Liu M S, Davignon J, Kastelein J J, Brunzell J D, Hayden M R
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
J Biol Chem. 1992 Jan 25;267(3):1918-23.
We are studying naturally occurring mutations in the gene for lipoprotein lipase (LPL) to advance our knowledge about the structure/function relationships for this enzyme. We and others have previously described 11 mutations in human LPL gene and until now none of these directly involves any of the residues in the proposed Asp156-His241-Ser132 catalytic triad. Here we report two separate probands who are deficient in LPL activity and have three different LPL gene haplotypes, suggesting three distinct mutations. Using polymerase chain reaction cloning and DNA sequencing we have identified that proband 1 is a compound heterozygote for a G----A transition at nucleotide 721, resulting in a substitution of asparagine for aspartic acid at residue 156, and a T----A transversion, resulting in a substitution of serine for cysteine at residues 216. Proband 2 is homozygous for an A----G base change at nucleotide 722, leading to a substitution of glycine for aspartic acid at residue 156. The presence of these mutations in the patients and available family members was confirmed by restriction analysis of polymerase chain reaction-amplified DNA. In vitro site-directed mutagenesis and subsequent expression in COS cells have confirmed that all three mutations result in catalytically defective LPL. The two naturally occurring mutations, which both alter the same aspartic acid residue in the proposed Asp156-His241-Ser132 catalytic triad of human LPL, indicate that Asp156 plays a significant role in LPL catalysis. The Cys216----Ser mutation destroys a conserved disulfide bridge that is apparently critical for maintaining LPL structure and function.
我们正在研究脂蛋白脂肪酶(LPL)基因的自然发生突变,以增进我们对该酶结构/功能关系的了解。我们和其他人之前已经描述了人类LPL基因中的11种突变,到目前为止,这些突变都没有直接涉及到所提出的Asp156-His241-Ser132催化三联体中的任何残基。在此,我们报告了两名LPL活性缺乏且具有三种不同LPL基因单倍型的独立先证者,提示存在三种不同的突变。通过聚合酶链反应克隆和DNA测序,我们确定先证者1是核苷酸721处G→A转换的复合杂合子,导致第156位残基处天冬酰胺替代天冬氨酸,以及T→A颠换,导致第216位残基处丝氨酸替代半胱氨酸。先证者2在核苷酸722处为A→G碱基变化的纯合子,导致第156位残基处甘氨酸替代天冬氨酸。通过对聚合酶链反应扩增的DNA进行限制性分析,证实了患者及其现有家庭成员中存在这些突变。体外定点诱变及随后在COS细胞中的表达证实,所有三种突变均导致催化缺陷型LPL。这两种自然发生的突变均改变了人类LPL所提出的Asp156-His241-Ser132催化三联体中相同的天冬氨酸残基,表明Asp156在LPL催化中起重要作用。Cys216→Ser突变破坏了一个保守的二硫键,该二硫键显然对维持LPL的结构和功能至关重要。